טוען...
Virologic Response, Early HIV-1 Decay and Maraviroc Pharmacokinetics with the Nucleos(t)ide-free Regimen of MaravIroc plus Darunavir/ritonavir in a Pilot Study
OBJECTIVE: To address the need for nucleos(t)ide reverse transcriptase inhibitor (NRTI)-sparing regimens, we explored the virologic and pharmacokinetic characteristics of maraviroc plus ritonavir-boosted darunavir in a single-arm, open-label, 96-week study. METHODS: 24 antiretroviral-naïve R5 HIV-1-...
שמור ב:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4208821/ https://ncbi.nlm.nih.gov/pubmed/23797691 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0b013e3182a03d95 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|